rGCA-CS (n=19) | rGCA-TCZ (n=11) | aGCA (n=11) | p Value | Controls* (n=10) | p Value | |
---|---|---|---|---|---|---|
Age, years: mean (SD) | 73 (10) | 69 (8) | 72 (10) | 0.41 | 59 (10) | <0.01 |
Sex, female: number (%) | 12 (63) | 9 (82) | 9 (82) | 0.48 | 4 (40) | 0.07 |
Race, white: number (%) | 17 (89) | 10 (91) | 11 (100) | 0.78 | 11 (100) | 1.00 |
Relapsing disease: number (%) | 12 (63) | 11 (100) | 8 (73) | 0.06 | – | – |
Biopsy-proven disease: number (%) | 11 (58) | 5 (45) | 7 (64) | 0.78 | – | – |
Image compatible with large vessel vasculitis: number (%)† | 2 (11) | 4 (36) | 4 (36) | 0.16 | – | – |
Disease duration, months: median (IQR) | 25.5 (9.2; 54.1) | 35.7 (32.7; 70.4) | 34.9 (3.7; 60.3) | 0.73 | – | – |
Duration of CS treatment, months: median (IQR) | 18.4 (9.2; 54.1) | 28.4 (9.9; 67.9) | 34.5 (1.0; 58.0) | 0.90 | – | – |
Duration of TCZ treatment, months: median (IQR) | – | 18 (14.2; 28.5) | – | – | – | – |
Prior MTX use: number (%) | 6 (32) | 4 (36) | 3 (27) | 1.00 | – | – |
CS dose at time of sampling, mg/day: mean (SD) | 15.7 (18.3) | 0.2 (0.4) | 8.0 (6.8) | 0.02‡ | – | – |
Analysis: Analysis of variance, Kruskal-Wallis, Student's t-test and Fisher's exact test.
*Controls versus all patients with GCA.
†Indicates MR angiography, CT angiography or positron emission tomography.
‡rGCA-CS versus rGCA-TCZ.
aGCA, active GCA; CS, corticosteroids (prednisone); GCA, giant cell arteritis; MTX, methotrexate; rGCA-CS, GCA in remission on CS; rGCA-TCZ, GCA in remission on TCZ without or without CS; TCZ, tocilizumab.